4 independant, multicenter, prospective, signle-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of durvalumab when prescribed with tazemetostat, separately, in distinct cohorts of solid tumors:~cohort A: patients with pancreatic cancer~cohort B: patients with colorectal cancer not MSI-H or MMR-deficient~cohort C: patients with metastatic solid tumors with positive interferon gamma signature and/or tertiary lymphoid structure positive~cohort D: patients with soft-tissue sarcoma
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.